Yahoo Finance3d
Nammi Therapeutics doses first subject in trial of QXL138AM for multiple myeloma
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced solid tumours and multiple myeloma. The dosing was conducted at The ...
Yahoo Finance6d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- Nammi Therapeutics ... solid tumor indications with high CD138 prevalence and multiple myeloma) with primary endpoints focused on safety and tolerability ...
Pharmabiz3d
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...
PipelineReview.com5d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
About Nammi Therapeutics, Inc. Nammi Therapeutics ... dose expansion in three cohorts (two solid tumor indications with high CD138 prevalence and multiple myeloma) with primary endpoints focused on ...